Ocular Therapeut (OCUL)

Jan 17, 2025, 7:00 AM EST - 19 hours ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 14, 2025, 7:00 AM EST - 3 days ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Dec 30, 2024, 12:16 PM EST - 18 days ago

Ocular Is Now Thoroughly Derisked

Dec 10, 2024, 7:30 AM EST - 5 weeks ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 6 weeks ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Nov 26, 2024, 7:30 AM EST - 7 weeks ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 14, 2024, 10:34 AM EST - 2 months ago

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:30 AM EST - 2 months ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 6, 2024, 7:30 AM EST - 2 months ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Oct 15, 2024, 7:30 AM EDT - 3 months ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 11, 2024, 5:50 AM EDT - 3 months ago

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

AMD

Oct 9, 2024, 7:30 AM EDT - 3 months ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Sep 25, 2024, 7:30 AM EDT - 4 months ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 5, 2024, 7:30 AM EDT - 4 months ago

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 4, 2024, 7:30 AM EDT - 4 months ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Aug 9, 2024, 12:53 PM EDT - 5 months ago

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:30 AM EDT - 5 months ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2024, 7:10 AM EDT - 5 months ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Jul 31, 2024, 7:30 AM EDT - 6 months ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 7:30 AM EDT - 6 months ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 10, 2024, 8:00 AM EDT - 6 months ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jun 20, 2024, 9:13 AM EDT - 7 months ago

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

SWKS BFH IRTC TRU

Jun 13, 2024, 4:05 PM EDT - 7 months ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 5, 2024, 7:30 AM EDT - 8 months ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 4, 2024, 4:05 PM EDT - 8 months ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2024, 2:01 PM EDT - 8 months ago

Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough

Jun 1, 2024, 5:30 AM EDT - 8 months ago

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

May 7, 2024, 4:05 PM EDT - 9 months ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 6, 2024, 8:16 PM EDT - 9 months ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2024, 7:30 AM EDT - 9 months ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

May 3, 2024, 7:30 AM EDT - 9 months ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

May 1, 2024, 7:30 AM EDT - 9 months ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

Apr 18, 2024, 7:00 AM EDT - 9 months ago

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Apr 15, 2024, 7:00 AM EDT - 9 months ago

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Apr 9, 2024, 7:30 AM EDT - 10 months ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Apr 6, 2024, 10:00 AM EDT - 10 months ago

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Mar 26, 2024, 7:30 AM EDT - 10 months ago

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

Mar 11, 2024, 4:05 PM EDT - 11 months ago

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

Mar 5, 2024, 7:30 AM EST - 11 months ago

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

Feb 22, 2024, 7:32 AM EST - 11 months ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

Feb 22, 2024, 7:31 AM EST - 11 months ago

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

Feb 22, 2024, 7:30 AM EST - 11 months ago

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

Feb 20, 2024, 6:00 AM EST - 11 months ago

2 Solid Quant-Rated Growth Stocks With High Consensus Upside Potential (SA Quant)

FAT

Feb 19, 2024, 9:00 AM EST - 11 months ago

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctiviti

Feb 15, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

Feb 13, 2024, 7:37 AM EST - 1 year ago

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Feb 11, 2024, 4:27 AM EST - 1 year ago

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

Jan 25, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Dec 18, 2023, 4:01 PM EST - 1 year ago

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Dec 13, 2023, 10:09 PM EST - 1 year ago

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock